| [1] |
Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease[J].Mov Disord, 2005, 20(10): 1255-1263.
|
| [2] |
Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom[J]. Mov Disord, 2004, 19(9): 1043-1049.
|
| [3] |
Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R)[J]. Age Ageing, 2005, 34(3): 268-273.
|
| [4] |
de Lau LM, Schipper CM, Hofman A, et al. Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study[J]. Arch Neurol, 2005, 62(8):1265-1269.
|
| [5] |
Wang Q, Zhang Z, Li L, et al. Assessment of cognitive impairment in patients with Parkinson's disease: prevalence and risk factors[J]. Clin Interv Aging, 2014, 9: 275-281.
|
| [6] |
Hely MA, Morris JG, Reid WG, et al. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years[J]. Mov Disord, 2005, 20(2): 190-199.
|
| [7] |
Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years[J]. Mov Disord, 2008, 23(6): 837-844.
|
| [8] |
Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study[J]. Arch Neurol, 2003, 60(3):387-392.
|
| [9] |
Levy G, Tang MX, Louis ED, et al. The association of incident dementia with mortality in PD[J].Neurology, 2002, 59(11): 1708-1713.
|
| [10] |
谭玉燕，陈生弟．帕金森病痴呆的临床特征及治疗进展[J]．中华神经科杂志，2006，39(6): 413-415.
|
| [11] |
陈晓春，叶钦勇．帕金森病痴呆的发病机制与治疗[J]．中国现代神经疾病杂志，2009，9(3): 221-223.
|
| [12] |
陈生弟，中华医学会神经病学分会帕金森病及运动障碍学组．中国帕金森病治疗指南(第二版)[J]．中华神经科杂志，2009，42(5): 352-355.
|
| [13] |
Zhou MZ, Gan J, Wei YR, et al. The association between non-motor symptoms in Parkinson's disease and age at onset[J]. Clin Neurol Neurosurg, 2013, 115(10): 2103-2107.
|
| [14] |
Hughes TA, Ross HF, Musan S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease[J]. Neurology, 2000, 54(8): 1596-602.
|
| [15] |
Marder K, Tang MX, Cote L, et al. The frequency and associated risk factors for dementia in patients with Parkinson's disease[J]. Arch Neurol, 1995, 52(7): 695-701.
|
| [16] |
Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort[J]. J Neurol Neurosurg Psychiatry, 2013, 84(11): 1258-1264.
|
| [17] |
Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease[J]. Ann Neurol, 2007, 62(2): 145-153.
|
| [18] |
Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important[J]? Brain, 2011, 134(Pt 5): 1493-1505.
|
| [19] |
Anang JB, Gagnon JF, Bertrand JA, et al. Predictors of dementia in Parkinson disease: a prospective cohort study[J]. Neurology, 2014, 83(14): 1253-1260.
|
| [20] |
Chen L, Yu C, Fu X, et al. Using the montreal cognitive assessment scale to screen for dementia in Chinese patients with Parkinson's disease[J]. Shanghai Arch Psychiatry, 2013, 25(5): 296-305.
|
| [21] |
Marder K, Flood P, Cote L, et al. A pilot study of risk factors for dementia in Parkinson's disease[J]. Mov Disord, 1990, 5(2): 156-61.
|
| [22] |
Marder K, Tang MX, Alfaro B, et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia[J]. Neurology, 1998, 50(4): 1141-1143.
|
| [23] |
Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging[J]. Neurology, 1997, 48(6): 1517-1521.
|
| [24] |
Maki PM, Henderson VM. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on[J]. Climacteric, 2012, 15(3): 256-62.
|
| [25] |
Zoccolella S, dell'Aquila C, Abruzzese G, et al. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia[J]. Mov Disord, 2009, 24(7): 1028-1033.
|
| [26] |
Glatt SL, Hubble JP, Lyons K, et al. Risk factors for dementia in Parkinson's disease: effect of education[J]. Neuroepidemiology, 1996, 15(1): 20-25.
|
| [27] |
Hu MT, Szewczyk-Krolikowski K, Tomlinson P, et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort[J]. Mov Disord, 2014, 29(3): 351-359.
|
| [28] |
Ebmeier KP, Calder SA, Crawford JR, et al. Clinical features predicting dementia in idiopathic Parkinson's disease: a follow-up study[J]. Neurology, 1990, 40(8): 1222-1224.
|
| [29] |
Levy G, Tang MX, Cote LJ, et al. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study[J]. Mov Disord, 2002, 17(2): 250-257.
|
| [30] |
Fitts W, Weintraub D, Massimo L, et al. Caregiver report of apathy predicts dementia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2015, 21(8): 992-995.
|
| [31] |
Aarsland D, Kvaloy JT, Andersen K, et al. The effect of age of onset of PD on risk of dementia[J]. J Neurol, 2007, 254(1): 38-45.
|
| [32] |
Alves G, Larsen JP, Emre M, et al. Changes in motor subtype and risk for incident dementia in Parkinson's disease[J]. Mov Disord, 2006, 21(8): 1123-1130.
|
| [33] |
Lyros E, Messinis L, Papathanasopoulos P. Does motor subtype influence neurocognitive performance in Parkinson's disease without dementia? [J] Eur J Neurol, 2008, 15(3): 262-267.
|
| [34] |
Pedersen KF, Larsen JP, Tysnes OB, et al. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study[J]. JAMA Neurol, 2013, 70(5): 580-6.
|
| [35] |
Postuma RB, Bertrand JA, Montplaisir J, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study[J]. Mov Disord, 2012, 27(6): 720-726.
|
| [36] |
Uc EY, McDermott MP, Marder KS, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort[J]. Neurology, 2009, 73(18): 1469-1477.
|
| [37] |
Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease[J]. Neurology, 2010, 75(12): 1055-1061.
|
| [38] |
Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study[J]. Parkinsonism Relat Disord, 2013, 19(8): 717-724.
|
| [39] |
Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study[J]. Lancet Neurol, 2011, 10(3): 230-40.
|
| [40] |
Chen-Plotkin AS, Hu WT, Siderowf A, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease[J].Ann Neurol, 2011, 69(4): 655-663.
|
| [41] |
俱西驰，屈秋民，王伟，等．血清尿酸水平与帕金森病认知功能障碍的关系[J]．南京医科大学学报(自然科学版)，2013，33(1): 59-61.
|
| [42] |
Andreadou E, Nikolaou C, Gournaras F, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration[J]. Clin Neurol Neurosurg, 2009, 111(9): 724-728.
|
| [43] |
Gonzalez-Aramburu I, Sanchez-Juan P, Sierra M, et al. Serum uric acid and risk of dementia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2014, 20(6): 637-639.
|
| [44] |
张玉虎，甘蓉，聂坤，等．帕金森病认知障碍与血尿酸水平的相关性分析[J]．国际神经病学神经外科学杂志，2013，40(3): 216-219.
|
| [45] |
Williams-Gray CH, Goris A, Saiki M, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease[J]. J Neurol, 2009, 256(3): 493-498.
|
| [46] |
Sidransky E, Lopez G. The link between the GBA gene and parkinsonism[J]. Lancet Neurol, 2012, 11(11): 986-998.
|
| [47] |
Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort[J]. Brain, 2013, 136(Pt 2): 392-399.
|
| [48] |
Duncan GW, Firbank MJ, O'Brien JT, et al. Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease[J]? Mov Disord, 2013, 28(4): 425-438.
|
| [49] |
Pan PL, Shi HC, Zhong JG, et al. Gray matter atrophy in Parkinson's disease with dementia: evidence from meta-analysis of voxel-based morphometry studies[J]. Neurol Sci, 2013, 34(5): 613-619.
|
| [50] |
Xu Y, Yang J, Hu X, et al. Voxel-based meta-analysis of gray matter volume reductions associated with cognitive impairment in Parkinson's disease[J]. J Neurol, 2016, Epub.
|
| [51] |
Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia[J]. Neuropsychopharmacology, 2013, 38(6): 938-949.
|
| [52] |
Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia[J].Neuroimage, 2008, 39(3): 1027-1033.
|